Vireo Growth (VREOF) Other Operating Expenses (2020 - 2026)
Vireo Growth (VREOF) reported Other Operating Expenses of $10.8 million for Q1 2026, up 730.77% on a YoY basis from $1.3 million in Q1 2025, and down 20.28% sequentially from $13.5 million in Q4 2025.
Vireo Growth (VREOF) Other Operating Expenses (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Other Operating Expenses data on file, last reported at $10.8 million in Q1 2026.
- For the quarter ending Q1 2026, Other Operating Expenses rose 730.77% year-over-year to $10.8 million; the trailing twelve-month figure through Mar 2026 stood at $37.1 million (up 443.1% YoY), and the FY2025 full-year result was $21.9 million, up 900.14% from the prior year.
- Other Operating Expenses retreated to $10.8 million in Q1 2026, from $13.5 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $13.5 million in Q4 2025 to a low of -$8.6 million in Q4 2022.
- A 5-year average of $2.0 million and a median of $168359.0 in 2022 frame the typical range for Other Operating Expenses.
- Across the five-year window, Other Operating Expenses slumped 10958.5% in 2023 and jumped 49411.94% in 2025, its largest moves.
- Tracing VREOF's Other Operating Expenses over 5 years: stood at -$8.6 million in 2022, then soared by 94.43% to -$478476.0 in 2023, then jumped by 1515.95% to $6.8 million in 2024, then soared by 99.95% to $13.5 million in 2025, then dropped by 20.28% to $10.8 million in 2026.
- Business Quant data shows VREOF's Other Operating Expenses at $10.8 million in Q1 2026, $13.5 million in Q4 2025, and $6.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.80 Mn |
| Dec 31, 2025 | 13.55 Mn |
| Sep 30, 2025 | 6.09 Mn |
| Jun 30, 2025 | 6.65 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 6.77 Mn |
| Sep 30, 2024 | -12,349.00 |
| Jun 30, 2024 | -1.23 Mn |
| Mar 31, 2024 | -887,212.00 |
| Dec 31, 2023 | -478,476.00 |
| Sep 30, 2023 | -823,400.00 |
| Jun 30, 2023 | 719,679.00 |
| Mar 31, 2023 | 386,165.00 |
| Dec 31, 2022 | -8.59 Mn |
| Sep 30, 2022 | 7,583.00 |
| Jun 30, 2022 | -10,930.00 |
| Mar 31, 2022 | 168,359.00 |
| Dec 31, 2021 | 6.47 Mn |
| Mar 31, 2021 | 437,107.00 |
| Dec 31, 2020 | 3.37 Mn |